Instruction for use: Anandron

ATX code L02BB02 Nilutamide

Pharmacological group

Androgens, antiandrogens

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C61 Malignant neoplasm of prostate

Adenocarcinoma of the prostate, Hormone-dependent prostate cancer, Hormone-Resistant Prostate Cancer, Malignant tumor of prostate, Malignant neoplasm of prostate, Carcinoma of the prostate, Locally-distributed non-metastatic prostate cancer, Locally advanced prostate cancer, Locally spread prostate cancer, Metastatic prostatic carcinoma, Metastatic prostate cancer, Metastatic hormone-resistant prostate cancer, Non-metastatic prostate cancer, Incompatible prostate cancer, Prostate Cancer, Prostate cancer, Common prostate cancer, Testosterone-Depot Prostate Cancer

Composition and form of release

1 tablet contains nilutamide 50 mg; In a blister of 15 pcs., In a box of 6 blisters.

pharmachologic effect

Pharmacological action - antiandrogenic, antitumor.

It blocks the androgen receptors.

Indications

Metastatic prostate cancer.

Contraindications

Hypersensitivity, anemia, impaired liver function.

Side effects

Nausea, vomiting, disruption of accommodation, interstitial pulmonary syndrome, anemia.

Interaction

Strengthens the effects of propranolol, chlordiazepoxide, diazepam, theophylline, blocking their microsomal oxidation; Is incompatible with alcohol (antabuse effect).

Dosing and Administration

Inside, 300 mg / day for 4 weeks, then maintenance therapy - 150 mg / day.

Precautionary measures

Treatment should be discontinued if symptoms of pulmonary involvement, unexplained abdominal pain, signs of jaundice, increased serum transaminase levels (3-fold compared to normal), or a decrease in hemoglobin. It is necessary to refrain from drinking and driving.

storage Conditions

At a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life of Anandron

3 years.

Do not use after the expiry date printed on the package.